ArticleTranslational pediatrics2024
Preliminary comparison of net gain in final adult height of girls with early menarche treated with or without gonadotropin-releasing hormone agonist.
Article in Translational pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early menarche is associated with both physical and psychosocial problems. Based on psychological and physical health considerations, for girls with early menarche, some parents and physicians may elect to use gonadotropin-releasing hormone agonists (GnRHa) to delay menstruation. This study aimed to explore the effects of GnRHa treatment on the final height of girls with early menarche and build the models to predict the final adult height (FAH). Methods: Girls who experienced menarche between the ages of 8 and 10 years and were diagnosed with idiopathic central precocious puberty (ICPP) at Tianjin Medical University General Hospital between July 2017 and August 2023 were included in this study. Participants were divided into two groups based on treatment strategy: GnRHa-treated and GnRHa-untreated groups. Laboratory parameters including growth factors and basal gonadotropins were tested at diagnosis. The heights and weights of the participants were measured every three months. Bone radiographs of the left hand and wrist were assessed by professional appraisers to determine the bone age (BA), which was measured every 6 months after diagnosis. Results: Clinical data of 176 girls who experienced early menarche were retrospectively analyzed. For participants in the GnRHa-treated group (n=87), growth velocity (GV) showed significant differences between the first 6 months and second 6 months of treatment (P=0.01; 5.82±2.3 Conclusions: For girls who experienced menarche between the ages of 8 and 10 years, GnRHa treatment suppressed GV and skeletal maturity. The GAM provides a theoretical basis for pediatric endocrinologists in deciding whether to apply GnRHa treatment, determining the time to withdraw GnRHa treatment, and predicting the FAH of girls with early menarche.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.